Summary of Study ST001170

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000782. The data can be accessed directly via it's Project DOI: 10.21228/M8M10T This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Study ID	ST001170
Study Title	Timecourse on MCF-7 cells treated with different concentration of doxorubicin
Study Summary	MCF-7 cells treated with 10μM doxorubicin for 4h followed by subsequent withdrawl of the drug and cultured up to 48h.Doxurubicin-treated cells and control cells were collected at 0,12,24,36,and 48h. Meanwhile,MCF-7 cells continuously exposed to a low dosage of doxorubicin at 0.1μM for 96h. Doxorubicin-treated cells and control cells were collected at 0,24,48,72 and 96h.
Institute	China Pharmaceutical University
Last Name	Shao
First Name	Chang
Address	Tongjiaxiang #24, Nanjing, Jiangsu, 210000, China
Email	cici_shao@126.com
Phone	13951628679
Submit Date	2019-04-11
Raw Data Available	Yes
Raw Data File Type(s)	qgd
Analysis Type Detail	LC-MS
Release Date	2020-12-01
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR000782
Project DOI:	doi: 10.21228/M8M10T
Project Title:	Carbohydrates, amino acid and nucleotide studies
Project Summary:	Comparision of carbohydrates,amino acid and nucleotide between MCF-7 cells treated with different concentration of doxorubicin
Institute:	China Pharmaceutical University
Last Name:	Shao
First Name:	Chang
Address:	Tongjiaxiang #24, Nanjing, Jiangsu, 210000, China
Email:	cici_shao@126.com
Phone:	13951628679

Subject:

Subject ID:	SU001235
Subject Type:	Cultured cells
Subject Species:	Homo sapiens
Taxonomy ID:	9606
Gender:	Not applicable
Species Group:	Mammals

Factors:

Subject type: Cultured cells; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id	local_sample_id	hours	Doxorubicin dosage(μM)
SA080868	10_NC_12h_3	12	-
SA080869	10_NC_12h_4	12	-
SA080870	10_NC_12h_5	12	-
SA080871	10_NC_12h_2	12	-
SA080872	10_NC_12h_1	12	-
SA080873	10_12h_4	12	10
SA080874	10_12h_2	12	10
SA080875	10_12h_1	12	10
SA080876	10_12h_5	12	10
SA080877	10_12h_3	12	10
SA080878	10_NC_24h_4	24	-
SA080879	10_NC_24h_3	24	-
SA080880	10_NC_24h_1	24	-
SA080881	10_NC_24h_5	24	-
SA080882	0.1_NC_24h_2	24	-
SA080883	0.1_NC_24h_5	24	-
SA080884	0.1_NC_24h_3	24	-
SA080885	0.1_NC_24h_1	24	-
SA080886	0.1_NC_24h_4	24	-
SA080887	10_NC_24h_2	24	-
SA080888	0.1_24h_3	24	0.1
SA080889	0.1_24h_2	24	0.1
SA080890	0.1_24h_1	24	0.1
SA080891	0.1_24h_5	24	0.1
SA080892	0.1_24h_4	24	0.1
SA080893	10_24h_4	24	10
SA080894	10_24h_1	24	10
SA080895	10_24h_2	24	10
SA080896	10_24h_5	24	10
SA080897	10_24h_3	24	10
SA080898	10_NC_36h_2	36	-
SA080899	10_NC_36h_3	36	-
SA080900	10_NC_36h_4	36	-
SA080901	10_NC_36h_5	36	-
SA080902	10_NC_36h_1	36	-
SA080903	10_36h_1	36	10
SA080904	10_36h_2	36	10
SA080905	10_36h_4	36	10
SA080906	10_36h_3	36	10
SA080907	10_36h_5	36	10
SA080908	10_NC_48h_5	48	-
SA080909	10_NC_48h_4	48	-
SA080910	10_NC_48h_3	48	-
SA080911	10_NC_48h_2	48	-
SA080912	10_NC_48h_1	48	-
SA080913	0.1_NC_48h_4	48	-
SA080914	0.1_NC_48h_2	48	-
SA080915	0.1_NC_48h_1	48	-
SA080916	0.1_NC_48h_3	48	-
SA080917	0.1_NC_48h_5	48	-
SA080918	0.1_48h_4	48	0.1
SA080919	0.1_48h_3	48	0.1
SA080920	0.1_48h_2	48	0.1
SA080921	0.1_48h_1	48	0.1
SA080922	0.1_48h_5	48	0.1
SA080923	10_48h_3	48	10
SA080924	10_48h_2	48	10
SA080925	10_48h_1	48	10
SA080926	10_48h_4	48	10
SA080927	10_48h_5	48	10
SA080928	0.1_NC_72h_3	72	-
SA080929	0.1_NC_72h_4	72	-
SA080930	0.1_NC_72h_5	72	-
SA080931	0.1_NC_72h_2	72	-
SA080932	0.1_NC_72h_1	72	-
SA080933	0.1_72h_1	72	0.1
SA080934	0.1_72h_3	72	0.1
SA080935	0.1_72h_5	72	0.1
SA080936	0.1_72h_2	72	0.1
SA080937	0.1_72h_4	72	0.1
SA080938	0.1_NC_96h_1	96	-
SA080939	0.1_NC_96h_5	96	-
SA080940	0.1_NC_96h_2	96	-
SA080941	0.1_NC_96h_4	96	-
SA080942	0.1_NC_96h_3	96	-
SA080943	0.1_96h_1	96	0.1
SA080944	0.1_96h_3	96	0.1
SA080945	0.1_96h_2	96	0.1
SA080946	0.1_96h_5	96	0.1
SA080947	0.1_96h_4	96	0.1
SA080858	10_NC_0h_2	-	-
SA080859	10_NC_0h_3	-	-
SA080860	10_NC_0h_5	-	-
SA080861	0.1_NC_0h_1	-	-
SA080862	10_NC_0h_4	-	-
SA080863	10_NC_0h_1	-	-
SA080864	0.1_NC_0h_3	-	-
SA080865	0.1_NC_0h_2	-	-
SA080866	0.1_NC_0h_5	-	-
SA080867	0.1_NC_0h_4	-	-

Showing results 1 to 90 of 90

Showing results 1 to 90 of 90

Collection:

Collection ID:	CO001229
Collection Summary:	Cells were washed with cold PBS twice and then permeabilized with cold 80% methanol followed by a 20-minute incubation at -80℃. The cell lysates were centrifuges at 14000g for 5 mins and the supernatant were collected and evaporated to dryness.
Sample Type:	Cultured cells

Treatment:

Treatment ID:	TR001250
Treatment Summary:	MCF-7 cells were exposed to 10 μM doxorubicin for 4 hr followed by subsequent withdrawal of the drug. Meanwhile, MCF-7 cells continuously exposed to a low dosage of doxorubicin at 0.1 μM for 96 hr. Doxorubicin-treated cells and control cells were collected at different time.

Sample Preparation:

Sampleprep ID:	SP001243
Sampleprep Summary:	MCF-7 cells were harvested and permeabilized with cold (80% (v/v) methanol: water solution followed by a 20-min incubation at -80 ℃. A stock solution of 4-Chloro-DL-phenylalanine was pre-spiked into the methanol aqueous buffer to a final concentration of 1.5 μg/mL, which subsequently served as an internal standard (IS). The cell lysates were centrifuged at 14,000g for 5 min at 4 ℃, and the resultant supernatant were collected and evaporated to dryness. The samples were reconstituted in 100 μL of water (LC-MS grade) before analysis on an HPLC−MS/MS, and 20 μL was used for analysis. For each group of samples subjected to metabolomics analysis, five biological replicates were prepared.

Sampleprep ID:

SP001243

Sampleprep Summary:

MCF-7 cells were harvested and permeabilized with cold (80% (v/v) methanol: water solution followed by a 20-min incubation at -80 ℃. A stock solution of 4-Chloro-DL-phenylalanine was pre-spiked into the methanol aqueous buffer to a final concentration of 1.5 μg/mL, which subsequently served as an internal standard (IS). The cell lysates were centrifuged at 14,000g for 5 min at 4 ℃, and the resultant supernatant were collected and evaporated to dryness. The samples were reconstituted in 100 μL of water (LC-MS grade) before analysis on an HPLC−MS/MS, and 20 μL was used for analysis. For each group of samples subjected to metabolomics analysis, five biological replicates were prepared.

Chromatography:

Chromatography ID:	CH001404
Chromatography Summary:	The mobile phase consisted of solvent A (5 mM ammonium acetate, pH=9, and 5% acetonitrile) and solvent B (acetonitrile). The gradient was set as follows: 0–3 min, 85% B; 3–6 min, 85–30% B; 6–15 min, 30–2% B; 15–18 min, 2% B; 18–19 min, 2–85% B; 19–26 min, 85% B. The flow rate was set at 0.4 mL/min.
Instrument Name:	Shimadzu LC-30A
Column Name:	Waters XBridge Amide (100 x 4.6mm,3.5um)
Flow Gradient:	0-3 min, 85% B; 3-6 min, 85-30% B; 6-15 min, 30-2% B; 15-18 min, 2% B; 18-19 min, 2-85% B; 19-26 min, 85% B.
Flow Rate:	0.4 mL/min
Solvent A:	5% acetonitrile/95% water; 5 mM ammonium acetate, pH 9
Solvent B:	100% acetonitrile
Chromatography Type:	HILIC

Analysis:

Analysis ID:	AN001935
Analysis Type:	MS
Chromatography ID:	CH001404
Num Factors:	15
Num Metabolites:	54
Has Mz:	1
Has Rt:	1
Rt Units:	Minutes
Units:	normalized peak area